Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: A comparative study in glioblastoma cells;Inhibierung von EGFR und HER2 mit therapeutischen Antikörpern und siRNA: Eine vergleichende Studie in Glioblastomzellen

Strahlentherapie und Onkologie

Volumn 191, Issue 2, 2015, Pages 180-191

  Wichmann, Henri ^a   Güttler, Antje ^a   Bache, Matthias ^a   Taubert, Helge ^b   Rot, Swetlana ^a   Kessler, Jacqueline ^a   Eckert, Alexander W ^a   Kappler, Matthias ^a   Vordermark, Dirk ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Antibodies, monoclonal, humanized; Cetuximab; EGFR; Glioblastoma; HER2; Trastuzumab

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; SMALL INTERFERING RNA; TRASTUZUMAB; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL MIGRATION; CELL SURVIVAL; CLONOGENESIS; COMPARATIVE STUDY; CONTROLLED STUDY; GENE SILENCING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GROWTH RATE; HUMAN; HUMAN CELL; PROTEIN TARGETING; RADIOSENSITIVITY; RADIOSENSITIZATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; RADIATION DOSE; RADIATION RESPONSE; TUMOR CELL CULTURE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HUMANS; MOLECULAR TARGETED THERAPY; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 84922334953     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-014-0743-9     Document Type: Article

References (58)

1. Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathol 109:93–108
2. van den Bent MJ (2006) Adjuvant treatment of high grade gliomas. Ann Oncol 17:X186–X190
3. Johns TG, Mckay MJ, Cvrljevic AN et al (2010) Mab 806 Enhances the efficacy of Ionizing radiation in glioma xenografts expressing the De2–7 epidermal growth factor receptor. Int J Radiat Oncol Biol Phys 78:572–578
4. Fedrigo CA, Grivicich I, Schunemann DP et al (2011) Radioresistance of human glioma spheroids and expression of HSP70, p53 and EGFr. Radiat Oncol 6:156
5. Mukherjee B, McEllin B, Camacho CV et al (2009) EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 69:4252–4259
6. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505–516
7. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445–1453
8. Chakravarti A, Dicker A, Mehta M (2004) The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys 58:927–931
9. Yarden Y (2001) The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37:S3–S8
10. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137
11. Mineo JF, Bordron A, Quintion-Roue I et al (2006) Increasing of HER2 membranar density in human glioblastoma U251MG cell line established in a new nude mice model. J Neurooncol 76:249–255
12. Mineo JF, Bordron A, Baroncini M et al (2007) Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol 85:281–287
13. Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26:6469–6487
14. Nicholson RI, Gee JMW, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37:S9–S15
15. Rego RL, Foster NR, Smyrk TC et al (2010) Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer 102:165–172
16. Wichmann H, Guttler A, Bache M et al (2014) Inverse prognostic impact of ErbB2 mRNA and protein expression level in tumors of soft tissue sarcoma patients. Strahlenther Onkol
17. Slamon DJ, Clark GM, Wong SG et al (1987) Human-breast cancer—correlation of relapse and survival with amplification of the Her-2 Neu oncogene. Science 235:177–182
18. Andrulis IL, Bull SB, Blackstein ME et al (1998) Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 16:1340–1349
19. Shen KR, Zhang SD, Zhao L et al (2014) Role of EGFR as a prognostic factor for survival in head and neck cancer: a meta-analysis. Tumor Biol 35:2285–2295
20. Sartore-Bianchi A, Moroni M, Veronese S et al (2007) Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25:3238–3245
21. Bergonie J, Tribondeau L (1959) Interpretation of some results of radiotherapy and an attempt at determining a logical technique of treatment [De Quelques Resultats de la Radiotherapie et Essai de Fixation d’une Technique Rationnelle]. Radiat Res 11:587–588
22. Heinemann V, Stintzing S, Kirchner T et al (2009) Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 35:262–271
23. Mohan S, Heitzer E, Ulz P et al (2014) Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet 10:e1004271
24. Blick SKA, Scott LJ (2007) Cetuximab—a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 67:2585–2607
25. Kulkarni S, Hicks DG (2008) HER2-Positive early breast cancer and trastuzumab: A surgeon’s perspective. Ann Surg Oncol 15:1677–1688
26. Hahnel A, Wichmann H, Kappler M et al (2010) Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol 5:82
27. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New England J Med 354:567–578
28. Slamon D (2000) Herceptin: increasing survival in metastatic breast cancer. Eur J Oncol Nurs 4:24–29
29. Hudis CA (2007) Drug therapy: Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 357:39–51
30. Schulte A, Liffers K, Kathagen A et al (2013) Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ. Neuro-Oncol 15:1289–1301
31. Upez-Albaitero A, Ferris RL (2007) Immune activation by epidermal growth factor receptor-specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 133:1277–1281
32. Chen G, Kronenberger P, Teugels E et al (2012) Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. Bmc Med 10:28
33. Combs SE, Schulz-Ertner D, Roth W et al (2007) In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. Int J Radiat Oncol Biol Phys 68:873–882
34. Miqueli AD, Rolff J, Lemm M et al (2009) Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br J Cancer 100:950–958
35. Dittmann K, Mayer C, Fehrenbacher B et al (2005) Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280:31182–31189
36. Baumann M, Zips D, Krause M (2012) [Experimental tumor therapy]. Strahlenther Onkol 188:291–294
37. Le XF, Almeida MI, Mao WQ et al (2012) Modulation of MicroRNA-194 and cell migration by HER2-Targeting trastuzumab in breast cancer. Plos One 7:e41170
38. Yakes FM, Chinratanalab W, Ritter CA et al (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62:4132–4141
39. Longva KE, Pedersen NM, Haslekas C et al (2005) Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 116:359–367
40. Barok M, Isola J, Palyi-Krekk Z et al (2007) Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 6:2065–2072
41. Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S et al (2011) IL-12 enhances the antitumor actions of trastuzumab via NK Cell IFN-gamma production. J Immunol 186:3401–3409
42. Roda JM, Joshi T, Butchar JP et al (2007) The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor-positive tumor cells is enhanced by cytokines. Clin Cancer Res 13:6419–6428
43. Garrett JT, Olivares MG, Rinehart C et al (2011) Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 108:5021–5026
44. Wolf-Yadlin A, Kumar N, Zhang Y et al (2006) Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol 2:54
45. Faltus T, Yuan JP, Zimmer B et al (2004) Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia 6:786–795
46. Choudhury A, Charo J, Parapuram SK et al (2004) Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 108:71–77
47. Vollmann A, Vornlocher HP, Stempfl T et al (2006) Effective silencing of EGFR with RNAi demonstrates non-EGFR dependent proliferation of glioma cells. Int J Oncol 28:1531–1542
48. Lo HW, Hung MC (2006) Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 94:184–188
49. Kang CS, Zhang ZY, Jia ZF et al (2006) Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo. Cancer Gene Ther 13:530–538
50. Neve RM, Sutterluty H, Pullen N et al (2000) Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 19:1647–1656
51. Kumar N, Zaman MH, Kim HD et al (2006) A high-throughput migration assay reveals HER2-mediated cell migration arising from increased directional persistence. Biophys J 91:L32–L34
52. Toulany M, Rodemann HP (2010) Membrane receptor signaling and control of DNA repair after exposure to ionizing radiation. Nuklearmedizin 49:S26–S30
53. Lammering G, Valerie K, Lin PS et al (2001) Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin Cancer Res 7:682–690
54. Gao L, Li FS, Dong B et al (2010) Inhibition of Stat3 and Erbb2 suppresses tumor growth, enhances radiosensitivity, and Induces mitochondria-dependent apoptosis in glioma cells. Int J Radiat Oncol Biol Phys 77:1223–1231
55. Hasselbalch B, Lassen U, Poulsen HS et al (2010) Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling. Cancer Invest 28:775–787
56. Yang CF, Liu Y, Lemmon MA et al (2006) Essential role for Rac in heregulin beta 1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4. Mol Cell Biol 26:831–842
57. Ulu N, Henning RH, Guner S et al (2013) Intracellular transactivation of epidermal growth factor receptor by alpha(1A)-Adrenoceptor is mediated by phosphatidylinositol 3-Kinase Independently of activation of extracellular signal regulated kinases 1/2 and Serine-Threonine kinases in Chinese hamster ovary cells. J Pharmacol Exp Ther 347:47–56
58. Brodowicz T, Wiltschke C, Budinsky AC et al (1997) Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int J Cancer 73:875–879